Highlights Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Delayed Nasdaq Other stock markets 10:50:54 13/05/2024 pm IST			5-day change	1st Jan Change
1.77 ^USD	+2.35%		+9.93%	+2.77%

01/05	Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	CI
28/03	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	01/05	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	04/01	CI
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	06/12	CI
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	29/11	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus	28/23/28	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	19/22/19	CI
CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022	02/22/02	CI
Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	17/22/17	CI
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344	26/22/26	CI
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID 19	11/22/11	CI
Cocrystal Pharma Board Approves Reverse Stock Split to Help Maintain Nasdaq Listing; Shares Jump After Hours	04/22/04	MT
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344	08/22/08	CI
Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing	14/22/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Highlights

Filters